Continuous glucose monitor accuracy measure
Mean Absolute Relative Difference (MARD ) is a standard metric used to evaluate the accuracy ofcontinuous glucose monitoring systems ,[ 1] which gives the average amount a CGM sensor reading varies from the actualblood glucose .[ 2] It is calculated by taking the average of the absolute relative differences between the glucose readings reported by the CGM system and corresponding reference measurements, typically obtained through laboratory analysis orblood glucose meters .[ 3] A lower MARD value indicates greater accuracy, and it is commonly used in clinical research and regulatory evaluations to compare the performance of different CGM devices. It is also of note that MARD percentages can vary by person, even while using the same device.[ 1]
Device MARD Release year Notes Dexcom STS 20.3% 2006 [ 4] Dexcom Seven 17% 2007 [ 5] Dexcom Seven Plus 16% 2010 [ 5] Dexcom G4 Platinum 13.9% 2012 [ 6] Dexcom G5 Mobile 9% 2015 [ 7] Dexcom G6 9% 2018 [ 8] Dexcom G7 8.2% 2022 [ 9] Dexcom G7 15-Day 8% 2024 [ 10] FreeStyle Libre 1 13.7% 2014 [ 11] FreeStyle Libre 2 9.3% 2020 [ 12] FreeStyle Libre 3 7.8% 2022 [ 13]
^a b Freckmann, Guido; Mende, Jochen; Pleus, Stefan; Waldenmaier, Delia; Baumstark, Annette; Jendrike, Nina; Haug, Cornelia (24 March 2021)."Mean Absolute Relative Difference of Blood Glucose Monitoring Systems and Relationship to ISO 15197" .Journal of Diabetes Science and Technology .16 (5):1089– 1095.doi :10.1177/19322968211001402 .ISSN 1932-2968 .PMC 9445334 .PMID 33759584 . ^ "Diabetes Technology Highlights from ATTD 2025" . diaTribe Foundation. March 24, 2025. Retrieved2025-04-09 .^ Pleus, Stefan; Stuhr, Andreas; Link, Manuela; Haug, Cornelia; Freckmann, Guido (20 February 2021)."Variation of Mean Absolute Relative Differences of Continuous Glucose Monitoring Systems Throughout the Day" .Journal of Diabetes Science and Technology .16 (3):649– 658.doi :10.1177/1932296821992373 .ISSN 1932-2968 .PMC 9294578 .PMID 33615834 . ^ SUMMARY OF SAFETY AND EFFECTIVENESS DATA, DexCom STS ,Food and Drug Administration , 24 March 2006, accessed 8 April 2025^a b Dexcom G5 Advisory Committee Briefing Materials ,Dexcom , Clinical Chemistry and Clinical Toxicology Devices Panel, 21 July 2016, accessed 8 February 2025^ Matuleviciene, Viktorija; Joseph, Jeffrey I.; Andelin, Mervi; Hirsch, Irl B.; Attvall, Stig; Pivodic, Aldina; Dahlqvist, Sofia; Klonoff, David; Haraldsson, Börje; Lind, Marcus (November 2014)."A Clinical Trial of the Accuracy and Treatment Experience of the Dexcom G4 Sensor (Dexcom G4 System) and Enlite Sensor (Guardian REAL-Time System) Tested Simultaneously in Ambulatory Patients with Type 1 Diabetes" .Diabetes Technology & Therapeutics .16 (11):759– 767.doi :10.1089/dia.2014.0238 .ISSN 1520-9156 .PMC 4201312 .PMID 25233297 . ^ "FDA Approves Dexcom G5® Mobile Continuous Glucose Monitoring System" .investors.dexcom.com . Retrieved2025-04-09 .^ "Dexcom G6 & G7, What's New?" .ADCES . Retrieved2025-04-09 .^ "How Dexcom G7 Continuous Glucose Monitoring Works" .Dexcom . Retrieved2025-04-09 .^ Hale, Conor (2025-04-10)."Dexcom wins FDA clearance for 15-day G7 CGM sensor" .www.fiercebiotech.com . Retrieved2025-04-11 . ^ Boscari, F.; Galasso, S.; Facchinetti, A.; Marescotti, M.C.; Vallone, V.; Amato, A.M.L.; Avogaro, A.; Bruttomesso, D. (February 2018)."FreeStyle Libre and Dexcom G4 Platinum sensors: Accuracy comparisons during two weeks of home use and use during experimentally induced glucose excursions" .Nutrition, Metabolism and Cardiovascular Diseases .28 (2):180– 186.doi :10.1016/j.numecd.2017.10.023 .PMID 29258716 . ^ "Freestyle Libre 2 CGM | Abbott Newsroom" .www.abbott.com . Retrieved2025-09-30 .^ "FreeStyle Libre 3 System | Healthcare Professionals | Abbott" .pro.freestyle.abbott . Retrieved2025-09-30 .